Following a $104 million investment from Oak HC/FT, Vumedi has modernized peer-to-peer clinical education, with physicians now spending more than 4.3 million minutes a month learning on the platform
OAKLAND, Calif. — Nov. 10, 2026 — Vumedi, the peer-to-peer learning community for physicians, today announced expanded AI-powered learning capabilities that help doctors connect clinical questions with the experience of leading specialists faster. The expansion comes as physicians increasingly turn to AI to keep up with a growing volume of medical information.
Vumedi’s AI turns more than 100,000 physician-led videos and nearly 5,000 podcast episodes across more than 21 specialties into an on-demand clinical resource. Physicians ask a clinical question, and the AI surfaces the most relevant specialist perspectives, including expert-led content not available in the published literature, and synthesizes how multiple experts approach the same problem. Clinicians can then jump to the time-stamped moment in the underlying video or episode to see the full clinical context, from procedural technique to treatment sequencing.
Since launching less than a year ago, Vumedi’s AI tools have been used by more than 150,000 NPI-verified clinicians, generating more than 1 million interactions. Physicians who use the AI tools spend 3.5 times more time on the platform than non-AI users, a sign that faster access to relevant expertise leads to deeper learning rather than a shortened journey.
“AI is making it dramatically easier for physicians to get information. That makes access to real clinical experience more important,” said Roman Giverts, founder and CEO of Vumedi. “Some of the most valuable knowledge in medicine lives in how experienced physicians actually practice, including how they interpret new evidence, sequence treatments, perform procedures and manage the cases that aren’t straightforward. AI gives us a new way to make that collective experience more accessible on Vumedi, so physicians can get to the expertise they need faster without losing the depth and context that make it valuable.”
The expanded capabilities build on a $104 million Series B growth investment from Oak HC/FT. Vumedi has used that capital to invest in talent, R&D, product development and outreach, expanding the content, features and formats physicians use to learn from their peers. Selected engagement metrics include:
“Vumedi’s ability to deliver complex information and education in a trusted, clear and concise way has positioned the company as a leading education destination for providers,” said Andrew Adams, co-founder and managing partner of Oak HC/FT. “"With its enhanced AI capabilities, Vumedi is even better positioned to deliver greater value to the healthcare community, and we are proud to support the team in this next phase of growth.”
Studies, new therapies, data and treatment approaches are emerging faster than any individual physician can absorb alone. Many AI tools respond by retrieving or summarizing that literature. Vumedi goes further, grounding answers in how practicing specialists are applying new evidence in the clinic.
That distinction is becoming more important because physicians are continually being asked to incorporate new therapies, devices, procedures and evidence into practice. Research has found that the time required for treatments to reach peak adoption has grown from approximately two to three years to six to seven years.
“The volume of research coming out has increased significantly, and we no longer have the time to read every single publication,” said Dr. Mumtu S. Lalla of Beth Israel Deaconess Medical Center. “Patients are not as black and white as the guidelines sometimes make it seem, so hearing from experts on Vumedi helps contextualize the changes and new medications in the clinic setting. It’s really nice that Vumedi’s AI draws on those experts’ videos, rather than only the guidelines.”
As physician engagement has grown, so has Vumedi’s work with life sciences companies. These companies rely on key opinion leaders to help clinicians move from awareness of a new treatment to confident use.
“Biotech and pharmaceutical innovation succeeds when advances in treatment become everyday care. To do this, industry needs trusted communications platforms that help physicians translate emerging evidence into clinical practice,” said Vic Clavelli, biotech executive, independent board director at Vumedi and former North American president for Inflammation & Immunology at Pfizer. “With these new AI capabilities, Vumedi stands out from traditional media by bringing the voice of the opinion leader close to the physician right when they are making patient care decisions. These AI-enhanced capabilities make that expertise easy to find, so innovative therapeutics can become the standard of care.”
Vumedi will continue investing in AI and product development to make physician expertise more searchable and accessible across the formats physicians increasingly prefer.
Vumedi is the peer-to-peer learning community for physicians, where clinicians come to learn directly from the experts and peers advancing their field. Physicians turn to Vumedi to see how leading specialists perform procedures, evaluate new treatments and navigate complex cases, giving them practical, real-world knowledge alongside the published evidence. By connecting doctors to the collective experience of their community, Vumedi helps them stay current, build confidence in their decisions and bring the latest advances to patients faster. For more information, visit www.vumedi.com.
Oak HC/FT is a venture and growth equity firm specializing in technology and healthcare. Oak HC/FT guides companies and founders at every stage, from seed to growth, to create businesses that make a measurable and lasting impact. Founded in 2014, Oak HC/FT has invested in more than 120 portfolio companies and has more than $10 billion in assets under management. Oak HC/FT is headquartered in Stamford, CT, with an office in San Francisco, CA. Learn more at www.oakhcft.com.
Jackie Kahn, Partner at Oak HC/FT
jackie@oakhcft.com
Marely Arias
PRforVumedi@bospar.com